Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women

Core Insights - Medicus Pharma Ltd. has announced that its abstract on Teverelix has been accepted for presentation at the AACE Annual Meeting 2026, highlighting the company's focus on advancing clinical development programs for innovative therapeutics [1][2] Group 1: Teverelix Clinical Data - The accepted abstract titled "Evaluation of Teverelix, a Long-Acting GnRH Antagonist" presents results from two Phase 1 studies involving 48 healthy premenopausal women, assessing pharmacokinetics, pharmacodynamics, bone turnover, and safety [2] - Key findings indicate rapid and reversible hormone suppression with stable bone markers, demonstrating the potential of Teverelix in women's health, particularly for conditions like endometriosis affecting approximately 10% of women of reproductive age [3][7] - The studies showed that Teverelix achieved dose-dependent estradiol suppression, with levels reaching the clinically relevant Barbieri window (30–50 pg/mL), and sustained hormone suppression lasting up to two to three weeks post-injection [7] Group 2: Mechanism and Safety Profile - Teverelix operates as a long-acting injectable GnRH antagonist, providing immediate receptor antagonism and rapid suppression of LH, FSH, and downstream sex hormones without an initial surge [4][16] - The drug has not shown significant cardiovascular safety signals in prior studies, which is particularly relevant for advanced prostate cancer patients with elevated cardiovascular risk [5] Group 3: Development Strategy - Medicus aims to advance select programs through Phase 2 proof-of-concept studies and pursue strategic partnerships for late-stage development and commercialization [8] - The company is also advancing its SkinJect™ program for non-invasive treatment of basal cell carcinoma, with topline data expected in Q1 2026 [9][22] Group 4: Regulatory and Strategic Collaborations - Medicus has received regulatory approvals in the UK for expanding its Phase 2 study evaluating Doxorubicin Microneedle Array for basal cell carcinoma [21] - The company has entered a non-binding memorandum of understanding with Helix Nanotechnologies to explore collaboration on mRNA platform development [13]